Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Berlin-Chemie Menarini
STUDY OBJECTIVES
1. PRIMARY:
* Longitudinal myocardial velocities at rest (assessed by tissue Doppler echocardiography)
* Systolic functional reserve (calculated as the absolute and relative increase of the myocardial systolic velocities at peak stress from rest)
* Brain natriuretic peptide (BNP, NT-pro BNP) after a 6-months period of treatment with nebivolol versus metoprolol. An improvement of more than 20% of the myocardial resting velocities of systolic functional reserve is considered to be clinically relevant. The working hypothesis is that the improvement of subclinical left ventricular dysfunction after 6 months of treatment is going to be greater in patients who receive nebivolol than in those who receive metoprolol.
2. SECONDARY:
* Global systolic function (ejection fraction)
* Radial myocardial velocities
* Right ventricular function
* Global diastolic function
* Left ventricular mass index
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
aged 18 years or older, men and women, hospitalized and outpatients
with a history of primary arterial hypertension
with a daytime ambulatory blood pressure \>140 and/or \>90 mm Hg
with left ventricular hypertrophy: LVMI \> 125 g/m2 for men, and \> 110 g/m2 for women, by Devereux formula, as recommended by the ESH-ESC guidelines (14)
in sinus rhythm
consented, by signing the Informed Consent
You may not be if
Severe arterial hypertension (systolic blood pressure \> 180 mm Hg and/or diastolic blood pressure \> 110 mm Hg)
Any history of coronary heart disease (stable angina, acute coronary syndromes, myocardial infarction)
Any history of cerebrovascular disease
Renal impairment (creatinine \> 1.5 mg% for men, \> 1.4 mg% for women)
Left ventricular global systolic dysfunction (EF \< 45%)
More than mild valvar (mitral or aortic) regurgitation
Hypertrophic cardiomyopathy
Pericarditis
Cor pulmonale
Pregnancy or lactating women
Any significant co-morbidities
Contraindication to beta-blocker therapy
Concomitant treatment with other beta-blockers
Participation to another investigational study in the last 3 months
